CA
NZ
UK
AU
IND
US
…
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer; and INB-600, a gamma-Delta T cell engager. In addition, it is developing INB-619, a gamma-delta TCE targeting CD19 for potential applications in both oncology and autoimmune diseases. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
In8bio Inc is a clinical-stage biotechnology company focused on developing cell- and gene-based immunotherapies, primarily for oncology. Its long-term growth drivers include positive clinical trial data, regulatory approvals, and strategic partnerships or licensing that could expand the pipeline and commercialization opportunities, which may benefit investors seeking exposure to early-stage therapeutics.
The company faces material risks from clinical trial failures, regulatory setbacks, limited operating history and revenue, and likely need for additional financing that could dilute shareholders.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -19.44M | -30.44M | -30.01M | -28.52M | -14.65M |
| Net income | -19.44M | -30.44M | -30.01M | -27.42M | -14.65M |
| Selling general administrative | 9.65M | 12.64M | 13.51M | 14.46M | 7.31M |
| Selling and marketing expenses | - | - | 2.50M | - | - |
| Gross profit | -2.50M | -2.65M | -2.50M | - | - |
| Reconciled depreciation | 2.50M | 2.65M | 2.50M | 1.10M | 0.79M |
| Ebit | -19.44M | -29.60M | -30.01M | -29.62M | -14.65M |
| Ebitda | -16.94M | -26.94M | -27.51M | -28.52M | -13.87M |
| Depreciation and amortization | 2.50M | 2.65M | 2.50M | 1.10M | 0.79M |
| Operating income | -19.86M | -30.44M | -30.34M | -28.52M | -14.65M |
| Other operating expenses | 19.86M | 30.44M | 30.34M | 28.52M | 14.65M |
| Interest expense | - | - | - | 1.10M | 0.79M |
| Interest income | 0.42M | 0.23M | 0.00M | - | - |
| Net interest income | 0.42M | 0.23M | 0.00M | - | - |
| Income tax expense | - | - | -32.84M | -1.10M | -0.79M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 17.36M | 30.44M | 27.84M | 28.52M | 14.65M |
| Cost of revenue | 2.50M | 2.65M | 2.50M | - | - |
| Total other income expense net | 0.42M | -0.84M | 0.33M | - | - |
| Net income from continuing ops | -19.44M | -30.44M | -30.01M | -28.52M | -14.65M |
| Net income applicable to common shares | - | - | - | - | -14.65M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 32.28M | 20.94M | 33.71M | 33.04M | 42.22M |
| Intangible assets | - | - | - | 0.13M | - |
| Other current assets | 0.79M | 1.46M | 3.34M | 4.05M | 1.96M |
| Total liab | 4.72M | 6.47M | 8.77M | 10.31M | 4.04M |
| Total stockholder equity | 27.56M | 14.48M | 24.94M | 22.73M | 38.18M |
| Other current liab | 1.63M | 1.05M | 2.96M | 2.34M | 1.24M |
| Common stock | 0.01M | 0.01M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.01M | 0.01M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -141.10M | -121.66M | -91.22M | -61.21M | -32.69M |
| Other assets | - | - | - | - | 0.41M |
| Cash | 27.09M | 11.12M | 21.28M | 18.18M | 37.02M |
| Total current liabilities | 3.16M | 3.08M | 5.39M | 5.82M | 2.26M |
| Net debt | -24.31M | -6.09M | -16.39M | -12.31M | -34.61M |
| Short term debt | 1.22M | 1.65M | 1.51M | 1.39M | 0.63M |
| Short long term debt total | 2.78M | 5.03M | 4.89M | 5.87M | 2.41M |
| Other stockholder equity | 168.64M | 136.13M | 116.15M | 83.94M | 70.87M |
| Property plant equipment | - | - | - | - | 2.83M |
| Total current assets | 27.88M | 12.58M | 24.62M | 22.23M | 38.98M |
| Net tangible assets | - | - | - | - | 38.18M |
| Accounts payable | 0.31M | 0.39M | 0.92M | 2.09M | 0.40M |
| Accumulated other comprehensive income | - | - | - | - | -42.22M |
| Non currrent assets other | 0.15M | 0.28M | 0.26M | 0.38M | 0.41M |
| Non current assets total | 4.40M | 8.37M | 9.08M | 10.80M | 3.24M |
| Capital lease obligations | 2.78M | 5.03M | 4.89M | 5.87M | 2.41M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.19M | -0.60M | -3.71M | -0.31M |
| Change to liabilities | - | - | - | - | -0.32M |
| Total cashflows from investing activities | - | -0.19M | -0.60M | - | -0.31M |
| Net borrowings | -0.69M | -0.79M | -0.80M | - | -0.71M |
| Total cash from financing activities | 28.64M | 14.18M | 27.04M | 8.99M | 32.95M |
| Change to operating activities | - | - | - | - | -1.52M |
| Net income | -19.44M | -30.44M | -30.01M | -28.52M | -14.65M |
| Change in cash | 15.93M | -10.15M | 3.10M | -18.84M | 19.14M |
| Begin period cash flow | 11.39M | 21.54M | 18.18M | 37.27M | 18.14M |
| End period cash flow | 27.31M | 11.39M | 21.28M | 18.43M | 37.27M |
| Total cash from operating activities | -12.71M | -24.15M | -23.34M | -24.12M | -13.51M |
| Issuance of capital stock | 27.07M | 9.94M | 24.56M | 9.54M | 36.33M |
| Depreciation | 1.77M | 2.65M | 2.50M | 1.10M | 0.79M |
| Other cashflows from investing activities | - | -0.08M | - | - | - |
| Other cashflows from financing activities | 28.64M | 5.04M | 3.28M | 0.06M | -2.66M |
| Change to netincome | - | - | - | - | 2.19M |
| Capital expenditures | 0.00M | 0.10M | 0.60M | 3.71M | 0.31M |
| Change in working capital | 1.04M | -1.41M | -0.20M | -0.17M | -1.84M |
| Stock based compensation | 3.19M | 5.00M | 4.37M | 3.47M | 2.19M |
| Other non cash items | 0.73M | 0.04M | 4.37M | - | 2.98M |
| Free cash flow | -12.71M | -24.25M | -23.94M | -27.83M | -13.82M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| INAB In8bio Inc |
0.01 0.95% |
0.88 | - | - | - | 0.58 | -1.15 |
| NVO Novo Nordisk A/S |
-0.54 1.32% |
40.55 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.37 0.43% |
544.66 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-2.77 0.29% |
956.64 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer; and INB-600, a gamma-Delta T cell engager. In addition, it is developing INB-619, a gamma-delta TCE targeting CD19 for potential applications in both oncology and autoimmune diseases. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
| Name | Title | Year Born |
|---|---|---|
| Mr. Tai-Wei Ho | Co-Founder, Pres, CEO & Director | 1976 |
| Dr. Lawrence S. Lamb Ph.D. | Exec. VP, Co-Founder & Chief Scientific Officer | 1954 |
| Mr. Patrick McCall CPA | CFO & Sec. | 1983 |
| Dr. Kate Rochlin Ph.D. | Chief Operating Officer | 1981 |
| Dr. Trishna Goswami M.D. | Chief Medical Officer | NA |
| Dr. Kenneth R. LaMontagne Ph.D. | Sr. VP of Bus. Devel. | NA |
| Mr. Tai-Wei Ho | Co-Founder, President, CEO & Director | 1977 |
| Dr. Trishna Goswami M.D. | Chief Medical Officer | 1978 |
| Dr. Lawrence S. Lamb Ph.D. | Executive VP, Co-Founder & Chief Scientific Officer | 1954 |
| Mr. Patrick McCall CPA | CFO & Secretary | 1983 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.40%
Communication Services
-0.45%
Consumer Cyclical
-0.55%
Consumer Defensive
-0.01%
Energy
-0.01%
Financial Services
-0.40%
Financials
-0.15%
Healthcare
-1.15%
Industrials
-0.46%
Real Estate
-0.29%
Technology
-1.22%
Utilities
-0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+0.55%
Please wait processing your request...